Article
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Cancer medicine - 1 Jul 2022
Liu Binliang, Yi Zongbi, Guan Yanfang, Ouyang Quchang, Li Chunxiao, Guan Xiuwen, Lv Dan, Li Lixi, Zhai Jingtong, Qian Haili, Xu Binghe, Ma Fei, Zeng Yixin
Abstract excerpt
PURPOSE: We used targeted capture sequencing to analyze TP53-mutated circulating tumor DNA (ctDNA) in metastatic breast cancer patients and to determine whether TP53 mutation has predictive value for anti-human epidermal growth factor receptor 2 (HER2) treatment for in HER2 amplification-positive patients (HER2+) and HER2 mutation-positive, amplification-negative (HER2-/mut) patients. PATIENTS AND METHODS: TP53...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.